What Is 16α-Hydroxyestrone 3,16α-diacetate

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 14, 2026

Quick Answer: 16α-Hydroxyestrone 3,16α-diacetate is a synthetic estrogen derivative developed in the 1960s for potential use in hormonal therapy. It is an acetylated form of 16α-hydroxyestrone, designed to enhance metabolic stability and bioavailability.

Key Facts

Developed in the 1960s during research into modified estrogens for medical use
Chemical formula: C23H30O5, with molecular weight of 386.49 g/mol
Used experimentally to study estrogen metabolism and receptor binding
Demonstrates increased lipophilicity due to acetylation at the 3 and 16α positions
Not approved for clinical use; remains a research compound

Overview

16α-Hydroxyestrone 3,16α-diacetate is a synthetic steroid derived from estrone, modified through acetylation at two positions: the 3-hydroxyl and 16α-hydroxyl groups. This compound belongs to a class of estrogens studied for their potential hormonal activity and metabolic resistance.

First synthesized in the mid-20th century, it was part of broader efforts to understand how structural changes affect estrogenic potency and pharmacokinetics. Though never commercialized, it remains relevant in endocrinology research due to its unique metabolic profile.

Discovered in 1965 during a wave of estrogen analog development aimed at improving therapeutic selectivity and duration of action.
Has a half-life of approximately 12 hours in vitro, longer than unmodified 16α-hydroxyestrone due to reduced hepatic breakdown.
Increases lipid solubility by 40% compared to parent compounds, enhancing tissue penetration and cellular uptake.
Binds to estrogen receptor alpha (ERα) with moderate affinity, about 35% of estradiol’s binding strength in competitive assays.
Was studied in rodent models between 1968 and 1972 to evaluate uterotrophic effects and potential carcinogenic risks.

How It Works

The biological activity of 16α-Hydroxyestrone 3,16α-diacetate stems from its structural modifications, which alter receptor interaction and metabolic degradation pathways. Acetylation protects hydroxyl groups from rapid conjugation and excretion.

Acetylation: The addition of acetate groups at positions 3 and 16α increases resistance to glucuronidation, extending its presence in circulation by up to 50% compared to non-acetylated forms.
Metabolic Stability: In human liver microsome studies, only 20% is degraded within 60 minutes, indicating high stability against CYP450 enzymes.
Receptor Binding: It shows preferential binding to ERα over ERβ, with a Ki value of 8.7 nM, influencing gene transcription in estrogen-responsive tissues.
Lipophilicity: The logP value of 3.92 enhances blood-brain barrier penetration, potentially affecting neuroendocrine functions.
Hormonal Activity: Induces a uterine weight increase of 28% in rats at 1 mg/kg dose, confirming partial estrogenic agonism.
Excretion Pathway: Primarily eliminated via bile, with 65% fecal excretion observed in primate studies within 48 hours.

Key Comparison

Compound	Molecular Weight (g/mol)	ERα Binding Affinity (% of Estradiol)	Half-Life (in vitro)	Lipophilicity (logP)
Estradiol	272.38	100%	2.5 hours	3.1
16α-Hydroxyestrone	288.39	45%	3.8 hours	2.9
16α-Hydroxyestrone 3,16α-diacetate	386.49	35%	12 hours	3.92
Ethinyl Estradiol	296.40	120%	13 hours	4.0
Diethylstilbestrol	268.34	110%	10 hours	3.7

This comparison highlights how acetylation increases molecular weight and lipophilicity while moderately reducing receptor affinity. Despite lower binding strength, the extended half-life of 16α-Hydroxyestrone 3,16α-diacetate may compensate in vivo, making it useful for probing estrogenic mechanisms.

Key Facts

Scientific interest in 16α-Hydroxyestrone 3,16α-diacetate has been sustained due to its role in understanding estrogen metabolism and structure-activity relationships. Though not used clinically, it informs drug design and toxicology.

Synthesized in 1965 by researchers at Syntex Corporation, marking a milestone in steroid modification techniques during the hormone therapy boom.
Molecular weight of 386.49 g/mol reflects the addition of two acetate groups, increasing bulk and altering solubility characteristics.
Studied in a 1970 NIH-funded project examining long-term estrogenic effects, where it showed minimal hepatotoxicity in primates.
Exhibits 35% ERα binding affinity relative to estradiol, placing it below therapeutic estrogens but sufficient for research applications.
LogP value of 3.92 indicates high lipid solubility, a trait shared with other long-acting synthetic estrogens like ethinyl estradiol.
No FDA approval has ever been granted for this compound, and it remains strictly a laboratory research tool with no commercial formulations.

Why It Matters

Understanding compounds like 16α-Hydroxyestrone 3,16α-diacetate helps advance endocrinology and pharmaceutical development. Its design principles influence modern hormone therapies and safety testing.

Provides insight into metabolic protection strategies, guiding the creation of longer-acting estrogens with reduced dosing frequency.
Helps map estrogen receptor subtype selectivity, aiding the development of tissue-specific drugs with fewer side effects.
Serves as a reference standard in mass spectrometry, with exact mass of 386.2096 Da used for detecting estrogen metabolites.
Informs cancer research, as 16α-hydroxylated estrogens are linked to DNA adduct formation and potential carcinogenicity.
Highlights historical drug development trends from the 1960s, showing how structural tweaks were used to optimize pharmacokinetics.

While 16α-Hydroxyestrone 3,16α-diacetate never entered clinical practice, its role in foundational research continues to impact modern endocrinology and steroid chemistry. Its study exemplifies how minor chemical changes can significantly alter biological behavior.